technology+classifications+%3e+therapeutics - Available Technologies | Rutgers University Innovation Ventures

Search Results - technology+classifications+%3e+therapeutics

98 Results Sort By:
Repurposing H1 and H2 antihistamines for the treatment of erythropoietic protoporphyria
​ Invention Summary: Erythropoietic protoporphyria (EPP) is a severe genetic disorder caused by defects in heme biosynthesis, leading to the accumulation of protoporphyrin IX (PP-IX) in the liver. This accumulation results in cholestasis and, in the most severe cases, end-stage liver failure, necessitating liver transplantation or leading to...
Published: 2/4/2025   |   Inventor(s): Bishr Omary, Ning Kuo
Keywords(s):  
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Rare Disease
Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; } ​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that...
Published: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Microglia Cell Therapy for the Treatment of Neurodegenerative Diseases
​ Human Microglia Invention Summary: Alzheimer’s Disease (AD) accounts for over 60% of dementia cases in people over 65. Individuals with Down Syndrome (DS) are at higher risk for AD and myeloid leukemia due to somatic mutations in hematopoietic cells. Interestingly, some DS individuals with AD neuropathology do not experience cognitive...
Published: 1/31/2025   |   Inventor(s): Peng Jiang, Mengmeng Jin
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Photolabile Sulfinate Protecting Groups for SuFEx synthesis of sulfonyl fluorides, sulfonamides, and sulfones with applications in drug discovery and manufacture
​Photo-labile SPGs protect sulfur-containing compounds in cross-coupling, acidic, and basic conditions. SPGs will convert to sulfonyl fluoride upon light exposure (See preprint below). Invention Summary: Sulfur-derived functional groups such as sulfonyl fluorides, sulfonamides, and sulfones have a significant role in the synthesis of complex...
Published: 1/30/2025   |   Inventor(s): Matthew Moschitto, Twinkle Patel, Ramkrishna Laha
Keywords(s):  
Category(s): Technology Classifications > Therapeutics
Enterovirus D68 capsid inhibitors as antivirals
​ Plaque assay results of Jun11-46-1 and Jun11-54-1 against EV-D68 US/MO/14-18947. Invention Summary: Enterovirus D68 (EV-D68) is an RNA virus that mainly affects children and results in moderate to severe respiratory illness, with the most extreme cases resulting in muscle weakness, paralysis, and death. Currently, there are no antivirals...
Published: 1/27/2025   |   Inventor(s): Jun Wang, Yanmei Hu, Kan Li
Keywords(s): Antibacterial, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
​ Non-covalent direct inhibition of the Keap1-Nrf2 PPI resulting in upregulation of ARE-gene expression. Thus, increase ARE-controlled cytoprotective oxidative stress response enzymes in the development of therapeutic and preventive agents for a number of diseases and conditions. Invention Summary: The Keap1-Nrf2-ARE system could protect...
Published: 1/14/2025   |   Inventor(s): Longqin Hu, Ahmed Ali
Keywords(s):  
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
Identification of NFAT5 as a novel target for preventing KRAS targeted therapy resistance
​ Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Invention Summary: Resistance to KRAS targeted therapy in cancers involves epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. However, the mechanism underlying EMT associated KRAS resistance...
Published: 1/6/2025   |   Inventor(s): Pingping Hou, Daiyong Deng
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
MYC Program as a biomarker of response to treatment with Enzalutamide
​ Invention Summary: Administration of Enzalutamide has been shown to improve patient survival overall, yet patients respond differently to the drug with nearly half either not responding or developing resistance over time. Unfortunately, patients that fail Enzalutamide treatment are left with no targeted therapeutic option, and progress to...
Published: 12/12/2024   |   Inventor(s):  
Keywords(s):  
Category(s): Technology Classifications > Cancer, Technology Classifications > Diagnostics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
1 2 3 4 5 6 7 8 9 10